This site is intended for healthcare professionals

Ultragenyx Canada announces Health Canada approval of Crysvita for the treatment of tumour induced osteomalacia in adults.

Read time: 1 mins
Last updated:15th Sep 2021
Published:15th Sep 2021
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced that Crysvita (burosumab injection) has been approved by Health Canada for the treatment of Tumour Induced Osteomalacia (TIO) in adults.
Condition: Tumor-Induced Osteomalacia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest